Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $56.00

Dianthus Therapeutics (NASDAQ:DNTH - Free Report) had its price target upped by Raymond James from $51.00 to $56.00 in a research note published on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts also recently issued reports on the company. Oppenheimer initiated coverage on Dianthus Therapeutics in a report on Thursday, October 3rd. They set an "outperform" rating and a $48.00 price objective on the stock. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They set an "outperform" rating and a $58.00 target price on the stock. Wedbush lowered their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a research report on Friday, August 9th. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a research report on Friday, July 26th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of "Buy" and a consensus target price of $45.86.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH traded down $0.84 during midday trading on Friday, reaching $29.06. The company's stock had a trading volume of 168,296 shares, compared to its average volume of 177,036. The business's fifty day simple moving average is $27.75 and its 200-day simple moving average is $26.49. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The company has a market capitalization of $853.49 million, a P/E ratio of -5.25 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. On average, analysts forecast that Dianthus Therapeutics will post -2.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently modified their holdings of the business. Quest Partners LLC increased its stake in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after purchasing an additional 1,124 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $112,000. American Century Companies Inc. raised its holdings in shares of Dianthus Therapeutics by 38.6% during the second quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock worth $788,000 after acquiring an additional 8,473 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at $236,000. Finally, WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics in the 2nd quarter worth $265,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.